
26/05/2025
⚠️ | A new investigational drug, Rhenium Obisbemeda (186RNL), developed at UT Health San Antonio, has shown remarkable potential to extend survival for patients with glioblastoma, the most common and aggressive primary brain tumor in adults. In a phase 1 clinical trial, the therapy more than doubled median survival and progression-free time, with no serious side effects reported. Delivered directly to tumors using advanced neuronavigation and nanoliposome technology, the treatment precisely targets cancer cells while sparing healthy tissue. With phase 2 now underway, this breakthrough offers renewed hope for patients and families facing this devastating disease.
Source: UT Health San Antonio